(Q27688906)
Statements
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib (English)
0 references
27 February 2014
0 references
57
0 references
4
0 references
1170-87
0 references
1 reference